Novo Nordisk A/SOpportunity Rank #12(NVO) Intrinsic Value & DCF Analysis (2026)
Current Price
$48.18
Last updated: Jul 24, 2026
Price vs Intrinsic Value
Fundamental Score
Weighted across 6 signals
Narrative Score
No change vs previous
Trend Score
As of 2026-07-24
Still researching stocks one at a time?
Intrinziq helps you:
- Turn your stock-picking rules into repeatable strategies
- Find better setups across hundreds of stocks automatically
- Backtest your strategy before putting money to work
The intrinsic value of Novo Nordisk A/S (NVO) is estimated at $165.63 per share based on a 10-year discounted cash flow (DCF) analysis. At the current price of $48.18, the stock appears undervalued relative to its projected cash flow fundamentals. This estimate assumes a 6.77% long-term growth rate and an 8.00% discount rate (calculated: 7.55%), reflecting expected future free cash flow and cost of capital.
The intrinsic value of Novo Nordisk A/S (NVO) is estimated at $165.63 per share based on a 10-year discounted cash flow (DCF) analysis. At the current price of $48.18, the stock appears undervalued relative to its projected cash flow fundamentals. This estimate assumes a 6.77% long-term growth rate and an 8.00% discount rate (calculated: 7.55%), reflecting expected future free cash flow and cost of capital.Valuation Details
Capital Efficiency
The company is earning a higher return on invested capital than it costs to raise that capital — a sign of strong, efficient value creation.
Fundamental Details
Narrative Details
Trend Details
Investment Coach
- Monitor whether valuation discount remains above 10%.
- Confirm ROIC stays above cost of capital over coming quarters.
- Follow narrative trend for meaningful shifts in the score direction.
Free Cash Flow (in millions)
How Intrinziq Estimates Fair Value
Intrinziq estimates Novo Nordisk A/S's intrinsic value using a discounted cash flow (DCF) model based on free cash flow trends and a market-based discount rate. The model projects future cash flows over ten years and discounts them using a market return assumption to estimate fair value.
Novo Nordisk A/SHealthcare
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.